Table 2.
Follow-up data in the post-COVID medical assessment
| Laboratory and radiological examinations, n (%) | Visit 1 (n = 449) | Visit 2 (n = 435) |
| CRP >0.5 mg/l | 144 (32) | 81 (18.6) |
| Ferritin >150 ng/ml | 282 (62.8) | 135 (31) |
| D-dimer >243 ng/ml | 74 (16.5) | 31 (7.1) |
| Lactate dehydrogenase >250 U/l | 61 (13.5) | 18 (4.1) |
| 25-hydroxyvitamin D < 10 mcg/ml | 178 (39.6) | 71 (16.3) |
| Chest X-rays abnormalities | 224 (49.8) | 151 (34.7) |
| Clinical evaluation n, (%) | ||
| Overall PCS n, (%) | 322 (71.7) | 206 (45.9) |
| Systemic symptoms | ||
| Fatigue | 215 (47.9) | 151 (34.7) |
| Myalgias/arthralgias | 181 (40) | 112 (25.7) |
| Fever | 13 (2.9) | 2 (0.4) |
| Headache | 128 (28.5) | 66 (15.1) |
| Pneumological symptoms | ||
| Dyspnea/breathlessness | 228 (50.8) | 166 (38.2) |
| Cough | 134 (29.8) | 87 (20) |
| Chest pain | 129 (28.7) | 89 (20.4) |
| Neurological symptoms | ||
| ‘Brain fog' | 234 (52.1) | 191 (43.9) |
| Dizziness | 88 (19.6) | 13 (2.9) |
| Memory impairment | 186 (41.4) | 155 (35.6) |
| Anosmia | 289 (64.4) | 234 (53.7) |
| Ageusia/dysgeusia | 213 (47.4) | 217 (49.8) |
| Peripheral neuropathy | 133 (29.6) | 78 (17.9) |
| Cardiovascular symptoms | ||
| Tachyarrhytmias | 168 (37.4) | 91 (20.9) |
| Pericarditis/myocarditis | 31 (6.9) | 4 (0.9) |
| Psychiatric symptoms | ||
| Sleeping disorders | 280 (62.4) | 233 (53.6) |
| Post-traumatic stress disorder | 171 (38) | 134 (30.8) |
| Anxiety | 230 (51.2) | 144 (33.1) |
| Major depression | 105 (23.4) | 39 (8.9) |
| Psychosis | 51 (11.3) | 9 (2) |
| Behavior disorder | 23 (5.1) | 6 (1.4) |
| Other referred signs/symptoms | ||
| Weight loss | 186 (41.4) | 102 (23.4) |
| Hair loss | 289 (64.4) | 42 (9.6) |
| Diabetes | 109 (24.3) | 39 (8.9) |
| Hypertension | 116 (25.8) | 61 (14) |
| Psoriasis | 83 (18.5) | 18 (19) |
| Venous thromboembolism | 41 (9.1) | 12 (2.7) |
| Thyroid dysfunction | 66 (20.5) | 35 (16.9) |